FMP
Akouos, Inc.
AKUS
NASDAQ
Inactive Equity
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.
13.29 USD
0 (0%)
Historical Prices
From:
To:
About
ceo
Dr. Emmanuel Simons M.B.A., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.akouos.comexchange
NASDAQ
Description
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The c...
CIK
0001722271
ISIN
US00973J1016
CUSIP
00973J101
Address
645 Summer Street
Phone
857 410 1818
Country
US
Employee
103
IPO Date
Jun 26, 2020
Financial Statement
Earnings
AKUS Financial Summary
CIK
0001722271
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
00973J101
ISIN
US00973J1016
Country
US
Price
13.29
Beta
-0.56
Volume Avg.
725.97k
Market Cap
0
Shares
-
52-Week
2.315-13.6
DCF
0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-4.69
P/B
-
Website
https://www.akouos.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest AKUS News
InvestorPlace
Oct 18, 2022
Why Is Akouos (AKUS) Stock Up 85% Today?
There's notable merger news today as pharmaceutical giant Eli Lilly (NYSE: LLY ) entered into a definitive agreement to acquire Akouos (NASDAQ: AKUS ). Clearly, Eli Lilly is looking to expand further into gene therapies.
The Motley Fool
Oct 18, 2022
Why Akouos Stock Is on Fire Today
A buyout agreement is lighting a fire underneath the biotech's shares today.
Reuters
Oct 18, 2022
Eli Lilly to buy genetic medicine developer Akouos for $487 ...
Drugmaker Eli Lilly and Co will acquire genetic medicine developer Akouos Inc in a cash deal worth about $487 million.
Market Watch
Oct 18, 2022
Eli Lilly to acquire Akouos for up to about $610 million and...
Eli Lilly and Co. LLY, +0.41% said Tuesday it has entered an agreement to acquire Akouos Inc. AKUS, -5.14% , a company developing a portfolio of viral gene therapies for the treatment of inner ear conditions including hearing loss, for up to $610 million in cash. Under the terms of the deal, Akouos shareholders will receive $12.50 a share in cash, plus one non-tradeable contingent value right per share that entitles the holder to receive up to an additional $3.00 in cash, for a total considerati...
Zacks Investment Research
Oct 10, 2022
Akouos, Inc. (AKUS) Upgraded to Strong Buy: Here's Why
Akouos, Inc. (AKUS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research
Aug 18, 2022
Akouos, Inc. (AKUS) Upgraded to Buy: Here's Why
Akouos, Inc. (AKUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
GlobeNewsWire
May 4, 2022
Akouos to Present at Bank of America 2022 Healthcare Confere...
BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will participate in a presentation at the Bank of America 2022 Healthcare Conference on Tuesday, May 10 at 10:00 a.m. PDT in Las Vegas, Nevada.
GlobeNewsWire
Mar 24, 2022
Akouos to Participate in Upcoming March Virtual Investor Con...
BOSTON, March 24, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer will participate in two upcoming virtual investor conferences in March:
